-

Eurofins Technologies Announces World’s First AOAC Performance Tested MethodsSM Status for a Screening Method to Detect Aflatoxin M1

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of aflatoxin M1, I’screen AFLA M1 milk, has been granted AOAC Research Institute Performance Tested MethodsSM status (AOAC Cert. No. 072002) for use with raw bovine whole milk, skim milk and powdered milk.

The assay was developed by Eurofins Tecna, a biotechnology company with 25 years’ experience in mycotoxin screening in food and feedstuffs. Eurofins Tecna is part of the Eurofins Technologies’ group of companies.

Aflatoxins are mycotoxins produced by different strains of Aspergillus, which grow on agricultural commodities, with high moisture content, at relatively high temperatures. Aflatoxin M1 (AFM1) is a derivative of Aflatoxin B1 (AFB1) that is present in the milk of animals that have been fed with AFB1-contaminated feed.

Regulatory limits have been set worldwide for Aflatoxins in food and feed, as well as for AFM1 in milk. AFM1 limits in milk vary in different countries between 0.05 and 0.5 µg/Kg. In the European Union, the limit has been set at 0.05 µg/Kg.

The sensitivity of the I’screen Afla M1 milk assay allows the detection of aflatoxin M1 at concentrations below the regulatory limits set by the European Union. Thanks to the linearity of its dynamic range, it is possible to dilute samples and use the kit in compliance with non-EU regulations, which set concentrations of up to ten times higher than Europe.

The assay is compliant with ISO 14675:2003 (IDF 186:2003).

Receiving the AOAC Performance Tested MethodsSM status demonstrates Eurofins Technologies’ commitment to providing high quality test methods for our food safety customers. The I’screen AFLA M1 milk kit is the first screening method to receive AOAC approval for aflatoxin M1 analysis in milk commodities.

For more information, visit www.eurofins-technologies.com

About Eurofins Technologies

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a global provider of diagnostic technologies in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

About Eurofins – the global leader in bio-analysis

With over 48,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Contacts

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

More News From Eurofins Scientific

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF) EUROFINS SCIENTIFIC SE – E1013 2. Identi...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/02/2026 FR0014000MR3 10 000 68.3375 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/02/2026 FR0014000MR3 10 000 67.9091 XPAR EUROFINS SCIENTIFIC 529900JEHFM...

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical...
Back to Newsroom